Respiratory Medicine
Volume 103, Issue 12 , Pages 1838-1853 , December 2009

Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany

  • R. Diel

      Affiliations

    • Department of Pneumology, Medical School Hannover (MHH), Carl-Neuberg-Str.1, 30625 Hannover, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 1724578525.
    • ,
  • T. Schaberg

      Affiliations

    • Center of Pneumology, Deaconess Hospital Rotenburg, Rotenburg/Wümme, Germany
    • ,
  • R. Loddenkemper

      Affiliations

    • German Central Committee against Tuberculosis, Berlin, Germany
    • ,
  • T. Welte

      Affiliations

    • Department of Pneumology, Medical School Hannover (MHH), Carl-Neuberg-Str.1, 30625 Hannover, Germany
    • ,
  • A. Nienhaus

      Affiliations

    • Institution for Statutory Accident Insurance and Prevention in the Health and Welfare Services, Hamburg, Germany

Received 10 June 2009 ,Accepted 10 July 2009.

References 

  1. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole-blood IFN-γ assay for the development of active TB disease. Am J Respir Crit Care Med. 2008;177:1164–1170
  2. Chisholm D, Evans D. Economic evaluation in health: saving money or improving care?. J Med Econ. 2007;10:325–337
  3. Diel R, Forssbohm M, Loytved G, et al. Recommendations for environmental contact tracing in tuberculosis. German Central Committee against Tuberculosis. Pneumologie. 2007;58:657–665
  4. Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005;14:339–347
  5. Fryback DG, Chinnis JO, Ulvila JW. Bayesian cost-effectiveness analysis. An example using the GUSTO trial. Int J Technol Assess Health Care. 2001;17:83–97
  6. De Perio MA, Tsevat J, Roselle GA. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med. 2009;169:179–187
  7. Marra F, Marra CA, Sadatsafavi M. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis. 2008;12:1414–1424
  8. Salpeter SR, Salpeter EE. Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculisis exposure: a cost-effectiveness analysis. Infect Control Hosp Epidemiol. 2004;25:1056–1061
  9. Wrighton-Smith P, Zellweger J-P. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J. 2006;28:45–50
  10. Sahni R, Miranda C, Yen-Lieberman B. Does the implementation of an interferon-g release assay in lieu of a tuberculin skin test increase acceptance of preventive therapy for latent tuberculosis among healthcare workers?. Infect Control Hosp Epidemiol. 2009;30:197–199
  11. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res. 1970;17:28–106
  12. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making. 1985;5:157–177
  13. Hutubessy RCW, Baltussen RMPM, Evans DB, Barendregt JJ, Murray C. Stochastic league tables: communicating cost-effectiveness results to decision-makers. Health Econ. 2001;10:473–477
  14. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170:445–449
  15. Bock NN, Metzger BS, Tapia JR, Blumberg HM. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. AJRCCM. 1999;159:295–300
  16. American Thoracic Society . Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis. 1986;134:355–363
  17. Scharer L, Smith JP. Serum transaminase elevations and other hepativ abnormalities in patients receiving isoniazid. Ann Intern Med. 1969;71:1113–1120
  18. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin – a meta-analysis. Chest. 1991;99:465–471
  19. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 1999;(1):Art. No.: CD001363
  20. Thompson NJ. International Union Against Tuberculosis committee on prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60:555–564
  21. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978;117:991–1001
  22. Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ. Isoniazid related fatal hepatitis. West J Med. 1996;164:486–491
  23. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281:1014–1018
  24. Salpeter SR. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J Med. 1993;159:560–564
  25. Snider DE, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis. 1992;145:494–497
  26. Lo Bue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med. 2003;168:443–447
  27. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. Int J Tuberc Lung Dis. 1999;3:847–850
  28. Egsmose T, Ang'awa JOW, Poti SJ. The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bull World Health Organ. 1965;33:419–433
  29. John GT, Thomas PP, Thomas M, Jeyaseelan L, Jacob CK, Shastry JCM. A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients. Transplantation. 1994;57:1683–1684
  30. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis. 1962;85:490–510
  31. Robert-Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2006, Berlin; 2008.
  32. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk benefit and cost-effectiveness analysis. Ann Intern Med. 1997;127:1051–1061
  33. Diel R, Rappenhöner B, Schaberg T. The cost structure of lung tuberculosis in Germany. Eur J Health Econ. 2004;5:243–251
  34. Gesundheitsberichterstattung des Bundes . Diagnosedaten der Krankenhäuser ab 2000 (Eckdaten der vollstationären Patienten und Patientinnen). http://www.gbe-bund.de
  35. Einheitlicher Bewertungsmaßstab . EBM, Kassenärztliche Bundesvereinigung. http://www.kbv.de/8170.html
  36. Schulenburg JM, Greiner W, Jost F, et al. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation - dritte und aktualisierte Fassung des Hannoveraner Konsens. Gesundh ökon Qual mang. 2007;12:285–290
  37. Statistisches Bundesamt. Volkswirtschaftliche Gesamtrechungen; Fachserie 18, Reihe 1.2 2. Vierteljahr 2008, 2.15 Lohnkosten je Arbeitnehmer. Wiesbaden; 2008.
  38. Gesundheitsberichterstattung des Bundes . Arbeitsunfähigkeit bei AOK-Pflichtmit-gliedern ohne Rentner (Arbeitsunfähigkeitsfälle und Arbeitsunfähigkeitstage, Tage je Fall). Jahr. 2007;
  39. Diel R, Nienhaus A, Lange C, Schaberg T. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J. 2006;28:35–44

PII: S0954-6111(09)00228-5

doi: 10.1016/j.rmed.2009.07.008

Respiratory Medicine
Volume 103, Issue 12 , Pages 1838-1853 , December 2009

Article Tools

* Image Usage & Resolution